<?xml version="1.0" encoding="UTF-8"?>
<document id="DDI-DrugBank.d476">
    <sentence id="DDI-DrugBank.d476.s0" text="ZEBETA should not be combined with other beta-blocking agents.">
        <entity id="DDI-DrugBank.d476.s0.e0" charOffset="0-5"
            type="brand" text="ZEBETA"/>
        <entity id="DDI-DrugBank.d476.s0.e1" charOffset="41-60"
            type="group" text="beta-blocking agents"/>
        <ddi id="DDI-DrugBank.d476.s0.d0" e1="DDI-DrugBank.d476.s0.e0"
            e2="DDI-DrugBank.d476.s0.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d476.s1" text="Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of ZEBETA may produce excessive reduction of sympathetic activity.">
        <entity id="DDI-DrugBank.d476.s1.e0" charOffset="58-66"
            type="drug" text="reserpine"/>
        <entity id="DDI-DrugBank.d476.s1.e1" charOffset="71-82"
            type="drug" text="guanethidine"/>
        <entity id="DDI-DrugBank.d476.s1.e2" charOffset="167-172"
            type="brand" text="ZEBETA"/>
        <ddi id="DDI-DrugBank.d476.s1.d0" e1="DDI-DrugBank.d476.s1.e0"
            e2="DDI-DrugBank.d476.s1.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d476.s1.d1" e1="DDI-DrugBank.d476.s1.e1"
            e2="DDI-DrugBank.d476.s1.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d476.s2" text="In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that ZEBETA be discontinued for several days before the withdrawal of clonidine.">
        <entity id="DDI-DrugBank.d476.s2.e0" charOffset="46-54"
            type="drug" text="clonidine"/>
        <entity id="DDI-DrugBank.d476.s2.e1" charOffset="112-117"
            type="brand" text="ZEBETA"/>
        <entity id="DDI-DrugBank.d476.s2.e2" charOffset="177-185"
            type="drug" text="clonidine"/>
        <ddi id="DDI-DrugBank.d476.s2.d0" e1="DDI-DrugBank.d476.s2.e1"
            e2="DDI-DrugBank.d476.s2.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d476.s3" text="ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.">
        <entity id="DDI-DrugBank.d476.s3.e0" charOffset="0-5"
            type="brand" text="ZEBETA"/>
        <entity id="DDI-DrugBank.d476.s3.e1" charOffset="37-58"
            type="group" text="myocardial depressants"/>
        <entity id="DDI-DrugBank.d476.s3.e2" charOffset="108-126"
            type="group" text="calcium antagonists"/>
        <entity id="DDI-DrugBank.d476.s3.e3" charOffset="149-164"
            type="group" text="phenylalkylamine"/>
        <entity id="DDI-DrugBank.d476.s3.e4" charOffset="167-175"
            type="drug" text="verapamil"/>
        <entity id="DDI-DrugBank.d476.s3.e5" charOffset="182-196"
            type="group" text="benzothiazepine"/>
        <entity id="DDI-DrugBank.d476.s3.e6" charOffset="199-207"
            type="drug" text="diltiazem"/>
        <entity id="DDI-DrugBank.d476.s3.e7" charOffset="223-243"
            type="group" text="antiarrhythmic agents"/>
        <entity id="DDI-DrugBank.d476.s3.e8" charOffset="254-265"
            type="drug" text="disopyramide"/>
        <ddi id="DDI-DrugBank.d476.s3.d0" e1="DDI-DrugBank.d476.s3.e0"
            e2="DDI-DrugBank.d476.s3.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d476.s3.d1" e1="DDI-DrugBank.d476.s3.e0"
            e2="DDI-DrugBank.d476.s3.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d476.s3.d2" e1="DDI-DrugBank.d476.s3.e0"
            e2="DDI-DrugBank.d476.s3.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d476.s3.d3" e1="DDI-DrugBank.d476.s3.e0"
            e2="DDI-DrugBank.d476.s3.e4" type="advise"/>
        <ddi id="DDI-DrugBank.d476.s3.d4" e1="DDI-DrugBank.d476.s3.e0"
            e2="DDI-DrugBank.d476.s3.e5" type="advise"/>
        <ddi id="DDI-DrugBank.d476.s3.d5" e1="DDI-DrugBank.d476.s3.e0"
            e2="DDI-DrugBank.d476.s3.e6" type="advise"/>
        <ddi id="DDI-DrugBank.d476.s3.d6" e1="DDI-DrugBank.d476.s3.e0"
            e2="DDI-DrugBank.d476.s3.e7" type="advise"/>
        <ddi id="DDI-DrugBank.d476.s3.d7" e1="DDI-DrugBank.d476.s3.e0"
            e2="DDI-DrugBank.d476.s3.e8" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d476.s4" text="Concurrent use of rifampin increases the metabolic clearance of ZEBETA, resulting in a shortened elimination half-life of ZEBETA.">
        <entity id="DDI-DrugBank.d476.s4.e0" charOffset="18-25"
            type="drug" text="rifampin"/>
        <entity id="DDI-DrugBank.d476.s4.e1" charOffset="64-69"
            type="brand" text="ZEBETA"/>
        <entity id="DDI-DrugBank.d476.s4.e2" charOffset="122-127"
            type="brand" text="ZEBETA"/>
        <ddi id="DDI-DrugBank.d476.s4.d0" e1="DDI-DrugBank.d476.s4.e0"
            e2="DDI-DrugBank.d476.s4.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d476.s5" text="However, initial dose modification is generally not necessary."/>
    <sentence id="DDI-DrugBank.d476.s6" text="Pharmacokinetic studies document no clinically relevant interactions with other agents given concomitantly, including thiazide diuretics, digoxin, and cimetidine.">
        <entity id="DDI-DrugBank.d476.s6.e0" charOffset="118-135"
            type="group" text="thiazide diuretics"/>
        <entity id="DDI-DrugBank.d476.s6.e1" charOffset="138-144"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d476.s6.e2" charOffset="151-160"
            type="drug" text="cimetidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d476.s7" text="There was no effect of ZEBETA on prothrombin time in patients on stable doses of warfarin.">
        <entity id="DDI-DrugBank.d476.s7.e0" charOffset="23-28"
            type="brand" text="ZEBETA"/>
        <entity id="DDI-DrugBank.d476.s7.e1" charOffset="81-88"
            type="drug" text="warfarin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d476.s8" text="Risk of Anaphylactic Reaction: While taking beta-blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic.">
        <entity id="DDI-DrugBank.d476.s8.e0" charOffset="44-56"
            type="group" text="beta-blockers"/>
    </sentence>
    <sentence id="DDI-DrugBank.d476.s9" text="Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reactions.">
        <entity id="DDI-DrugBank.d476.s9.e0" charOffset="56-66"
            type="drug" text="epinephrine"/>
    </sentence>
</document>
